Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have earned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $7.25.

A number of research analysts recently weighed in on the stock. Ascendiant Capital Markets decreased their target price on shares of Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, November 21st. D Boral Capital upgraded shares of Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 3rd. D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 target price on shares of Plus Therapeutics in a research report on Thursday, December 11th. HC Wainwright reiterated a “buy” rating and set a $2.00 target price on shares of Plus Therapeutics in a report on Wednesday, November 26th. Finally, Zacks Research cut Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 11th.

Hedge Funds Weigh In On Plus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Susquehanna International Group LLP bought a new stake in Plus Therapeutics during the third quarter worth $46,000. Jane Street Group LLC acquired a new position in shares of Plus Therapeutics during the 2nd quarter worth about $41,000. Scientech Research LLC acquired a new position in shares of Plus Therapeutics during the 3rd quarter worth about $100,000. Finally, Altium Capital Management LLC bought a new stake in shares of Plus Therapeutics in the 3rd quarter valued at about $628,000. 3.28% of the stock is owned by institutional investors.

Plus Therapeutics Stock Performance

NASDAQ:PSTV opened at $0.57 on Friday. The stock has a 50-day simple moving average of $0.59 and a 200 day simple moving average of $0.51. Plus Therapeutics has a 52-week low of $0.16 and a 52-week high of $2.31. The company has a market cap of $78.13 million, a PE ratio of -0.30 and a beta of 0.82.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings results on Thursday, October 30th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The business had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $1.50 million. On average, research analysts predict that Plus Therapeutics will post -2.3 earnings per share for the current fiscal year.

About Plus Therapeutics

Plus Therapeutics is a clinical?stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.